Hugh Davis of Aclaris (ACRS) awarded RSUs and stock options

Rhea-AI Filing Summary

Aclaris Therapeutics reported new equity awards to President and COO Hugh M. Davis, who also serves as a director. On February 2, 2026, he received 96,100 restricted stock units, each representing one share of common stock, and 336,300 employee stock options with a $3.61 exercise price.

The restricted stock units vest in four equal annual installments on the first through fourth anniversaries of February 2, 2026, contingent on his continuous service. The stock options become exercisable as 25% of the shares vest in four equal annual installments on the same anniversary dates, also subject to continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Davis Hugh M.

Role President and COO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	96,100	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	336,300	$0.00	--

Holdings After Transaction: Restricted Stock Units — 96,100 shares (Direct); Employee Stock Option (Right to Buy) — 336,300 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Hugh M.

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/02/2026		A		96,100		(2)	(2)	Common Stock	96,100	$0	96,100	D
Employee Stock Option (Right to Buy)	$3.61	02/02/2026		A		336,300		(3)	02/01/2036	Common Stock	336,300	$0	336,300	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

3. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 4 for ACRS report for Hugh M. Davis?

The Form 4 reports that Hugh M. Davis, President, COO and director of Aclaris Therapeutics, received equity awards on February 2, 2026, including new restricted stock units and employee stock options as part of his compensation package.

How many restricted stock units did Hugh M. Davis receive from Aclaris (ACRS)?

Hugh M. Davis received 96,100 restricted stock units. Each unit represents a contingent right to receive one share of Aclaris common stock, vesting over four years in equal annual installments starting on the first anniversary of February 2, 2026.

What stock options were granted to Hugh M. Davis by Aclaris Therapeutics?

Aclaris Therapeutics granted Hugh M. Davis 336,300 employee stock options with a $3.61 exercise price. These options relate to common stock and vest in four equal annual installments, beginning on the first anniversary of February 2, 2026, subject to continuous service.

What is the vesting schedule for Hugh M. Davis’s Aclaris restricted stock units?

The 96,100 restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026. Vesting requires Hugh M. Davis to remain in continuous service with Aclaris under the applicable equity plan.

How do the Aclaris stock options for Hugh M. Davis become exercisable?

The employee stock options become exercisable as 25% of the underlying shares vest in four equal annual installments. These installments occur on the first through fourth anniversaries of February 2, 2026, assuming Hugh M. Davis maintains continuous service with the company.

What is Hugh M. Davis’s role at Aclaris Therapeutics (ACRS)?

Hugh M. Davis serves as both President and Chief Operating Officer of Aclaris Therapeutics and is also a director. His status as an officer and director triggers ongoing reporting obligations for equity awards and other transactions in Aclaris securities.